New targeted drug enters first human tests for Hard-to-Treat cancers

NCT ID NCT06597721

Recruiting now Disease control Sponsor: Adcendo ApS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to find the safest dose and to see if the drug is tolerable, with early signs of tumor shrinkage also being monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ADCE-T02 (an antibody-drug conjugate targeting tissue factor)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early phase 1 trial focused on safety and dosing, so it is uncertain if ADCE-T02 will effectively shrink tumors or have manageable side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cabrini Hospital
RECRUITING

Malvern, Victoria, 3144, Australia
Highlands Oncology Group
RECRUITING

Rogers, Arkansas, 72758, United States
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, 6009, Australia
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Macquarie University Hospital
RECRUITING

Macquarie Park, New South Wales, 2109, Australia
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Peninsula and South Eastern Haematology and Oncology Group (PSEHOG)
RECRUITING

Frankston, Victoria, 3199, Australia
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Scientia Clinical Research
RECRUITING

Randwick, New South Wales, 2031, Australia
Southern Oncology Clinical Research Unit
RECRUITING

Bedford Park, South Australia, 5042, Australia
Yale University Cancer Center
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.